High Mobility Group A 1 Expression as a Poor Prognostic Marker Associated with Tumor Invasiveness in Gastric Cancer
Abstract
:1. Introduction
2. Materials and Methods
2.1. Tissue Microarray Construction
2.2. Immunohistochemistry and Quantification
2.3. Primary Antibody
2.4. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Jiang, Y.; Yu, Y. Transgenic and gene knockout mice in gastric cancer research. Oncotarget 2017, 8, 3696–3710. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Poh, A.R.; O’Donoghue, R.J.; Ernst, M.; Putoczki, T.L. Mouse models for gastric cancer: Matching models to biological questions. J. Gastroenterol. Hepatol. 2016, 31, 1257–1272. [Google Scholar] [CrossRef] [PubMed]
- Thrift, A.P.; El-Serag, H.B. Burden of gastric cancer. Clin. Gastroenterol. Hepatol. 2020, 18, 534–542. [Google Scholar] [CrossRef] [PubMed]
- Digklia, A.; Wagner, A.D. Advanced gastric cancer: Current treatment landscape and future perspectives. World J. Gastroenterol. 2016, 22, 2403–2414. [Google Scholar] [CrossRef] [PubMed]
- Song, Z.; Wu, Y.; Yang, J.; Yang, D.; Fang, X. Progress in the treatment of advanced gastric cancer. Tumour Biol. 2017, 39, 1010428317714626. [Google Scholar] [CrossRef] [Green Version]
- Tan, Z. Recent advances in the surgical treatment of advanced gastric cancer: A review. Med. Sci. Monit. 2019, 25, 3537–3541. [Google Scholar] [CrossRef]
- Garattini, S.K.; Basile, D.; Cattaneo, M.; Fanotto, V.; Ongaro, E.; Bonotto, M.; Negri, F.V.; Berenato, R.; Ermacora, P.; Cardellino, G.G.; et al. Molecular classifications of gastric cancers: Novel insights and possible future applications. World J. Gastrointest. Oncol. 2017, 9, 194–208. [Google Scholar] [CrossRef]
- Fassan, M.; Saraggi, D.; Balsamo, L.; Cascione, L.; Castoro, C.; Coati, I.; De Bernard, M.; Farinati, F.; Guzzardo, V.; Valeri, N.; et al. Let-7c down-regulation in Helicobacter pylori-related gastric carcinogenesis. Oncotarget 2016, 7, 4915–4924. [Google Scholar] [CrossRef] [Green Version]
- Meireles Da Costa, N.; Ribeiro Pinto, L.F.; Nasciutti, L.E.; Palumbo, A., Jr. The prominent role of HMGA proteins in the early management of gastrointestinal cancers. BioMed Res. Int. 2019, 2019, 2059516. [Google Scholar] [CrossRef]
- Cui, T.; Leng, F. Specific recognition of AT-rich DNA sequences by the mammalian high mobility group protein AT-hook 2: A SELEX study. Biochemistry 2007, 46, 13059–13066. [Google Scholar] [CrossRef]
- Shah, S.N.; Resar, L.M. High mobility group A1 and cancer: Potential biomarker and therapeutic target. Histol. Histopathol. 2012, 27, 567–579. [Google Scholar] [PubMed]
- Giannini, G.; Cerignoli, F.; Mellone, M.; Massimi, I.; Ambrosi, C.; Rinaldi, C.; Gulino, A. Molecular mechanism of HMGA1 deregulation in human neuroblastoma. Cancer Lett. 2005, 228, 97–104. [Google Scholar] [CrossRef] [PubMed]
- Mendez, O.; Perez, J.; Soberino, J.; Racca, F.; Cortes, J.; Villanueva, J. Clinical implications of extracellular HMGA1 in breast cancer. Int. J. Mol. Sci. 2019, 20, 5950. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Palumbo, A., Jr.; de Sousa, V.P.L.; Esposito, F.; De Martino, M.; Forzati, F.; Moreira, F.C.B.; Simão, T.D.A.; Nasciutti, L.E.; Fusco, A.; Pinto, L.F.R.; et al. Overexpression of HMGA1 figures as a potential prognostic factor in endometrioid endometrial carcinoma (EEC). Genes 2019, 10, 372. [Google Scholar] [CrossRef] [Green Version]
- Liau, S.S.; Rocha, F.; Matros, E.; Redston, M.; Whang, E. High mobility group AT-hook 1 (HMGA1) is an independent prognostic factor and novel therapeutic target in pancreatic adenocarcinoma. Cancer 2008, 113, 302–314. [Google Scholar] [CrossRef] [Green Version]
- Jun, K.H.; Jung, J.H.; Choi, H.J.; Shin, E.Y.; Chin, H.M. HMGA1/HMGA2 protein expression and prognostic implications in gastric cancer. Int. J. Surg. 2015, 24, 39–44. [Google Scholar] [CrossRef]
- Jin, G.H.; Shi, Y.; Tian, Y.; Cao, T.T.; Mao, Y.; Tang, T.Y. HMGA1 accelerates the malignant progression of gastric cancer through stimulating EMT. Eur. Rev. Med. Pharmacol. Sci. 2020, 24, 3642–3647. [Google Scholar]
- Menon, S.S.; Guruvayoorappan, C.; Sakthivel, K.M.; Rasmi, R.R. Ki-67 protein as a tumour proliferation marker. Clin. Chim. Acta 2019, 491, 39–45. [Google Scholar] [CrossRef]
- Pang, B.; Fan, H.; Zhang, I.Y.; Liu, B.; Feng, B.; Meng, L.; Zhang, R.; Sadeghi, S.; Guo, H.; Pang, Q. HMGA1 expression in human gliomas and its correlation with tumor proliferation, invasion and angiogenesis. J. Neurooncol. 2012, 106, 543–549. [Google Scholar] [CrossRef]
- Kloppel, G.; La Rosa, S. Correction to: Ki67 labeling index: Assessment and prognostic role in gastroenteropancreatic neuroendocrine neoplasms. Virchows Arch. 2018, 472, 515. [Google Scholar] [CrossRef] [Green Version]
- Luo, G.; Hu, Y.; Zhang, Z.; Wang, P.; Luo, Z.; Lin, J.; Cheng, C.; Yang, Y. Clinicopathologic significance and prognostic value of Ki-67 expression in patients with gastric cancer: A meta-analysis. Oncotarget 2017, 8, 50273–50283. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yilmaz, H.; Demirag, G.; Sullu, Y.; Yilmaz, A. Predictive significance of Ki-67 and platelet lymphocyte ratio in patients with gastric cancer receiving neoadjuvant FLOT chemotherapy. J. Coll. Physicians Surg. Pak. 2021, 30, 546–552. [Google Scholar] [PubMed]
- Xie, J.; Zhao, Y.; Zhou, Y.; He, Q.; Hao, H.; Qiu, X.; Zhao, G.; Xu, Y.; Xue, F.; Chen, J.; et al. Predictive value of combined preoperative carcinoembryonic antigen level and Ki-67 index in patients with gastric neuroendocrine carcinoma after radical surgery. Front. Oncol. 2021, 11, 533039. [Google Scholar] [CrossRef] [PubMed]
- Mansoori, B.; Mohammadi, A.; Shirjang, S.; Baradaran, B. HMGI-C suppressing induces P53/caspase9 axis to regulate apoptosis in breast adenocarcinoma cells. Cell Cycle 2016, 15, 2585–2592. [Google Scholar] [CrossRef]
- Fedele, M.; Pierantoni, G.M.; Berlingieri, M.T.; Battista, S.; Baldassarre, G.; Munshi, N.; Dentice, M.; Thanos, D.; Santoro, M.; Viglietto, G.; et al. Overexpression of proteins HMGA1 induces cell cycle deregulation and apoptosis in normal rat thyroid cells. Cancer Res. 2001, 61, 4583–4590. [Google Scholar] [CrossRef] [Green Version]
- Huang, K.-H.; Fang, W.-L.; Li, A.F.-Y.; Liang, P.-H.; Wu, C.-W.; Shyr, Y.-M.; Yang, M.-H. Caspase-3, a key apoptotic protein, as a prognostic marker in gastric cancer after curative surgery. Int. J. Surg. 2018, 52, 258–263. [Google Scholar] [CrossRef]
- Lertkiatmongkol, P.; Liao, D.; Mei, H.; Hu, Y.; Newman, P.J. Endothelial functions of platelet/endothelial cell adhesion molecule-1 (CD31). Curr. Opin. Hematol. 2016, 23, 253–259. [Google Scholar] [CrossRef] [Green Version]
- Winn, R.K.; Harlan, J.M. The role of endothelial cell apoptosis in inflammatory and immune diseases. J. Thromb. Haemost. 2005, 3, 1815–1824. [Google Scholar] [CrossRef]
- Ogut, B.; Ekinci, O.; Celik, B.; Unal, E.R.; Dursun, A. Comparison of the efficiency of transgelin, smooth muscle myosin, and CD31 antibodies for the assessment of vascular tumor invasion and free tumor deposits in gastric, pancreatic, and colorectal adenocarcinomas. Indian J. Pathol. Microbiol. 2020, 63, 25–31. [Google Scholar] [CrossRef]
- Li, Y.; Guo, X.B.; Wei, Y.H.; Kang, X.L. Serum CXCL13 and PECAM-1 can be used as diagnostic and prognostic markers in elderly patients with gastric cancer. Clin. Transl. Oncol. 2021, 23, 130–138. [Google Scholar] [CrossRef]
- Hopper, R.K.; Moonen, J.R.; Diebold, I.; Cao, A.; Rhodes, C.J.; Tojais, N.F.; Hennigs, J.K.; Gu, M.; Wang, L.; Rabinovitch, M. In pulmonary arterial hypertension, reduced BMPR2 promotes endothelial-to-mesenchymal transition via HMGA1 and its target Slug. Circulation 2016, 133, 1783–1794. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gonzalez, D.M.; Medici, D. Signaling mechanisms of the epithelial-mesenchymal transition. Sci. Signal. 2014, 7, re8. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lamouille, S.; Xu, J.; Derynck, R. Molecular mechanisms of epithelial-mesenchymal transition. Nat. Rev. Mol. Cell Biol. 2014, 15, 178–196. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhang, Y.; Weinberg, R.A. Epithelial-to-mesenchymal transition in cancer: Complexity and opportunities. Front. Med. 2018, 12, 361–373. [Google Scholar] [CrossRef] [Green Version]
- Mittal, V. Epithelial mesenchymal transition in tumor metastasis. Annu. Rev. Pathol. 2018, 13, 395–412. [Google Scholar] [CrossRef]
- Huang, R.; Huang, D.; Dai, W.; Yang, F. Overexpression of HMGA1 correlates with the malignant status and prognosis of breast cancer. Mol. Cell. Biochem. 2015, 404, 251–257. [Google Scholar] [CrossRef]
- Ma, Y.; Li, X.; Chen, S.; Du, B.; Li, Y. MicroRNA-4458 suppresses migration and epithelial-mesenchymal transition via targeting HMGA1 in non-small-cell lung cancer cells. Cancer Manag. Res. 2019, 11, 637–649. [Google Scholar] [CrossRef] [Green Version]
- Xie, J.; Chen, Q.; Zhou, P.; Fan, W. Circular RNA hsa_circ_0000511 improves epithelial mesenchymal transition of cervical cancer by regulating hsa-mir-296-5p/HMGA1. J. Immunol. Res. 2021, 2021, 9964538. [Google Scholar] [CrossRef]
- Zhong, J.; Liu, C.; Zhang, Q.-H.; Chen, L.; Shen, Y.-Y.; Chen, Y.-J.; Zeng, X.; Zu, X.-Y.; Cao, R.-X. TGF-beta1 induces HMGA1 expression: The role of HMGA1 in thyroid cancer proliferation and invasion. Int. J. Oncol. 2017, 50, 1567–1578. [Google Scholar] [CrossRef] [Green Version]
- Olea-Flores, M.; Zuniga-Eulogio, M.D.; Mendoza-Catalan, M.A.; Rodriguez-Ruiz, H.A.; Castaneda-Saucedo, E.; Ortuno-Pineda, C.; Padilla-Benavides, T.; Navarro-Tito, N. Extracellular-signal regulated kinase: A central molecule driving epithelial-mesenchymal transition in cancer. Int. J. Mol. Sci. 2019, 20, 2885. [Google Scholar] [CrossRef] [Green Version]
- Vincent, E.E.; Elder, D.J.; Thomas, E.C.; Phillips, L.; Morgan, C.; Pawade, J.; Sohail, M.; May, M.T.; Hetzel, M.R.; Tavaré, J.M. Akt phosphorylation on Thr308 but not on Ser473 correlates with Akt protein kinase activity in human non-small cell lung cancer. Br. J. Cancer 2011, 104, 1755–1761. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chen, X.-G.; Liu, F.; Song, X.-F.; Wang, Z.-H.; Dong, Z.-Q.; Hu, Z.-Q.; Lan, R.-Z.; Guan, W.; Zhou, T.-G.; Xu, X.-M.; et al. Rapamycin regulates Akt and ERK phosphorylation through mTORC1 and mTORC2 signaling pathways. Mol. Carcinog. 2010, 49, 603–610. [Google Scholar] [CrossRef] [PubMed]
- Liu, L.; Zhang, S.; Hu, L.; Liu, L.; Guo, W.; Zhang, J. HMGA1 participates in MHCC97H cell proliferation and invasion through the ILK/Akt/GSK3beta signaling pathway. Mol. Med. Rep. 2017, 16, 9287–9294. [Google Scholar] [CrossRef] [Green Version]
- Takaha, N.; Sowa, Y.; Takeuchi, I.; Hongo, F.; Kawauchi, A.; Miki, T. Expression and role of HMGA1 in renal cell carcinoma. J. Urol. 2012, 187, 2215–2222. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Y.; Ma, T.; Yang, S.; Xia, M.; Xu, J.; An, H.; Yang, Y.; Li, S. High-mobility group A1 proteins enhance the expression of the oncogenic miR-222 in lung cancer cells. Mol. Cell. Biochem. 2011, 357, 363–371. [Google Scholar] [CrossRef] [PubMed]
- Hanna, R.; Abdallah, J.; Abou-Antoun, T. A novel mechanism of 17-AAG therapeutic efficacy on HSP90 inhibition in MYCN-amplified neuroblastoma cells. Front. Oncol. 2020, 10, 624560. [Google Scholar] [CrossRef]
- Mendez, O.; Peg, V.; Salvans, C.; Pujals, M.; Fernandez, Y.; Abasolo, I.; Pérez, J.; Matres, A.; Valeri, M.; Gregori, J.; et al. Extracellular HMGA1 promotes tumor invasion and metastasis in triple-negative breast cancer. Clin. Cancer Res. 2018, 24, 6367–6382. [Google Scholar] [CrossRef] [Green Version]
Factors | HMGA1 Low Expression | HMGA1 High Expression | p-Value | |
---|---|---|---|---|
Age (years) | <65 | 38 (76.0%) | 12 (24.0%) | 0.015 |
≥65 | 109 (83.2) | 22 (16.8%) | ||
Gender | Female | 99 (81.1%) | 23 (18.9%) | 0.973 |
Male | 48 (81.4%) | 11 (18.6%) | ||
Differentiation | Well | 44 (84.6%) | 8 (15.4%) | 0.460 |
Moderate | 103 (79.8%) | 26 (20.2%) | ||
Stage | I and II | 60 (81.1%) | 14 (18.9%) | 0.970 |
III and IV | 87 (81.3%) | 20 (18.7%) |
Biomarkers | r | p-Value | |
---|---|---|---|
Proliferation | Ki-67 | 0.402 | <0.001 |
Apoptosis | Caspase 3 | 0.193 | <0.001 |
Angiogenesis | CD31 | 0.167 | 0.002 |
EMT | E-cadherin | 0.176 | 0.001 |
N-cadherin | 0.154 | 0.005 | |
Fibronectin | 0.340 | <0.001 | |
Tyrosine kinase | pAkt | 0.340 | <0.001 |
pErk | −0.109 | 0.048 | |
pSTAT3 | 0.003 | 0.950 | |
pAMPK | 0.022 | 0.691 |
Hazard Ratio (95% CI) | p-Value | ||
---|---|---|---|
HMGA1 expression | Low | Reference | |
High | 1.78 (1.01–3.14) | 0.045 | |
Age (years) | <65 | Reference | |
>=65 | 0.70 (0.41–1.18) | 0.184 | |
Gender | Female | Reference | |
Male | 0.74 (0.42–1.32) | 0.311 | |
Differentiation | Moderate | Reference | |
Well | 1.74 (0.94–3.34) | 0.079 | |
Stage | I and II | Reference | |
III and IV | 2.50 (1.44–4.35) | 0.001 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Chang, H.-P.; Sun, J.-T.; Cheng, C.-Y.; Liang, Y.-J.; Chen, Y.-L. High Mobility Group A 1 Expression as a Poor Prognostic Marker Associated with Tumor Invasiveness in Gastric Cancer. Life 2022, 12, 709. https://doi.org/10.3390/life12050709
Chang H-P, Sun J-T, Cheng C-Y, Liang Y-J, Chen Y-L. High Mobility Group A 1 Expression as a Poor Prognostic Marker Associated with Tumor Invasiveness in Gastric Cancer. Life. 2022; 12(5):709. https://doi.org/10.3390/life12050709
Chicago/Turabian StyleChang, Hung-Pin, Jen-Tang Sun, Chiao-Yin Cheng, Yao-Jen Liang, and Yen-Lin Chen. 2022. "High Mobility Group A 1 Expression as a Poor Prognostic Marker Associated with Tumor Invasiveness in Gastric Cancer" Life 12, no. 5: 709. https://doi.org/10.3390/life12050709